Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-058129
Filing Date
2025-04-24
Accepted
2025-04-24 16:37:31
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20250331.htm   iXBRL 10-Q 2091161
2 EX-10.1 vktx-ex10_1.htm EX-10.1 618636
3 EX-10.2 vktx-ex10_2.htm EX-10.2 269940
4 EX-10.3 vktx-ex10_3.htm EX-10.3 729135
5 EX-31.1 vktx-ex31_1.htm EX-31.1 17574
6 EX-31.2 vktx-ex31_2.htm EX-31.2 17550
7 EX-32.1 vktx-ex32_1.htm EX-32.1 13187
  Complete submission text file 0000950170-25-058129.txt   10058162

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250331.xsd EX-101.SCH 1032375
61 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250331_htm.xml XML 1439784
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 25868176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)